Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma Group Limited has issued 1,090,360 unquoted performance rights under its employee incentive scheme, effective 30 December 2025. The new equity-based awards, which are subject to transfer restrictions and will not be quoted on the ASX until those restrictions lapse, underscore the company’s ongoing use of long-term incentives to align employee and executive interests with shareholder value and support retention in a competitive pharmaceutical talent market.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company listed on the ASX under the code MYX. The company operates in the specialty and generic medicines sector, focusing on the development, manufacture and distribution of pharmaceutical products to domestic and international markets.
Average Trading Volume: 569,690
Technical Sentiment Signal: Sell
Current Market Cap: A$259.2M
Learn more about MYX stock on TipRanks’ Stock Analysis page.